- Home
- DHAI vs DTIL Comparison
DHAI vs DTIL Comparison
Compare DHAI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- DTIL
- Stock Information
- Founded
- DHAI 2007
- DTIL 2006
- Country
- DHAI United States
- DTIL United States
- Employees
- DHAI N/A
- DTIL N/A
- Industry
- DHAI
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- DHAI
- DTIL Health Care
- Exchange
- DHAI NYSE
- DTIL Nasdaq
- Market Cap
- DHAI 10.5M
- DTIL 51.6M
- IPO Year
- DHAI N/A
- DTIL 2019
- Fundamental
- Price
- DHAI $0.22
- DTIL $4.79
- Analyst Decision
- DHAI
- DTIL Strong Buy
- Analyst Count
- DHAI 0
- DTIL 2
- Target Price
- DHAI N/A
- DTIL $47.00
- AVG Volume (30 Days)
- DHAI 2.1M
- DTIL 85.2K
- Earning Date
- DHAI 07-14-2025
- DTIL 07-31-2025
- Dividend Yield
- DHAI N/A
- DTIL N/A
- EPS Growth
- DHAI N/A
- DTIL N/A
- EPS
- DHAI N/A
- DTIL N/A
- Revenue
- DHAI $69,573,000.00
- DTIL $51,141,000.00
- Revenue This Year
- DHAI N/A
- DTIL N/A
- Revenue Next Year
- DHAI N/A
- DTIL $30.20
- P/E Ratio
- DHAI N/A
- DTIL N/A
- Revenue Growth
- DHAI 5.40
- DTIL N/A
- 52 Week Low
- DHAI $0.12
- DTIL $3.61
- 52 Week High
- DHAI $3.67
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- DHAI 48.38
- DTIL 44.86
- Support Level
- DHAI $0.20
- DTIL $4.20
- Resistance Level
- DHAI $0.26
- DTIL $5.29
- Average True Range (ATR)
- DHAI 0.04
- DTIL 0.36
- MACD
- DHAI -0.00
- DTIL -0.03
- Stochastic Oscillator
- DHAI 23.33
- DTIL 36.88
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.